NYSE:JNJ
Johnson & Johnson (JNJ)
254.66
+9.78 (3.99%)
as of Jun 26, 2026, 8:00:00 pm Market Open.
696 watching
Financials 
Technical Analysis 0
Investor Insights
Jun 28, 2026, 12:00 amThis summary was created by AI, based on 10 opinions in the last 12 months.
Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.
Consensus
Positive
Valuation
Fair Value
Similar
PG
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly JNJ is a defensive holding that is trading below peer valuation (23x earnings vs 36x for peers). The company is preparing to spin off its consumer division in favour of more investment into its pharmaceutical and medical device divisions. It is reportedly making progress on a ground breaking ulcerative colitis treatment. We recommend placing a stop at $150, looking to achieve $190 -- upside over 15%. Yield 2.7% (Analysts’ price target is $187.82)
biotechnologypharmaceutical
HOLD
In process of spinning off consumer products, could lead to value accretion. At lower end of 52-week range, growth has slowed down from historic levels and this gives him pause. Middle valuation among older line pharma. "Blue chip" of pharma industry. He's OK with it, but his pick for portfolios is ELV.
biotechnologypharmaceutical
BUY
Continue to like the business.
Spinoff of consumer business is a good move.
Established business with good prospects.
Is a good defensive name(high dividend) for long term investors.
Will continue to hold.
JoAnne FeeneyOwned
biotechnologypharmaceutical
BUY
Healthcare is defensive because you have constant demand for these products and services. Investors should have exposure in this uncertain economy. Her pick here is JNJ, given its strong balance sheet. They offer pharmaceuticals, medical devices and consumer products, so are diversified. Aging demographics will fuel demand.
Christine PooleOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Sep 16/21, Up 3%) A solid return, considering the year we had. 60 years of consecutive dividend increases. Look at the spinout that's coming. Growth should accelerate. Long term story, not a trade story.
Darren SissonsOwned
biotechnologypharmaceutical
TOP PICK
She likes healthcare for being a defensive growth sector. JNJ's balance sheet is very strong, so lots of money to buy companies and grow. They spend a lot on R&D. 70% of revenues come from products that rank #1 or 2. 25% of revenues are from products launched within 5 years. Boasts powerful brands across all segments. Their pharma division is doing well, comprising 55% of company revenues. Drugs coming off-patent can be replaced by 14 drugs totaling a potential $5 billion in sales. They pay a 2.7% dividend they has been increasing for 60 straight years. (Analysts’ price target is $186.88)
Christine PooleOwned
biotechnologypharmaceutical
TOP PICK
Giant in pharma. Also medical and consumer. Likes pharma, as it's large and has scale. Patents are more insulated from cliffs than its peers. Well staggered expiry dates, diversified components. Spinoff of consumer division should unlock value. Outperformed S&P 500 in 5/6 of the last bear markets. Undemanding 17x earnings. Yield is 2.66%. (Analysts’ price target is $188.56)
Brian MaddenOwned
biotechnologypharmaceutical
TOP PICK
A traditional recession-proof company. Model price of $171 or so, a 4% overvaluation. Going to split off vaccine division, which is bullish for the stock. Not much upside, but you're looking for companies to get you through a recession deeper than a lot of people realize. Yield is 2.51%. (Analysts’ price target is $190.39)
Brian Acker, CAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
